AIM
ECYT

Acrospire Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Acrospire Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,735
Closed -$15K – 2751
2017
Q1 		$15K Sell
5,735
-20,326
-78% -$47K 0.01% 1756
2016
Q4 		$66K Buy
+26,061
New +$74.8K 0.03% 1223

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Acrospire Investment Management's ECYT Position: Q2 2017 in Review

Acrospire Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2017, closing a stake of 5,735 shares — an estimated $15K sold.

Acrospire Investment Management first reported a position in ECYT in Q4 2016 and held it in 2 quarters. The position peaked at $66K in Q4 2016. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

  • Acrospire Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 5,735 Endocyte, Inc. Common Stock shares in Q2 2017, an estimated $15K.
  • Acrospire Investment Management first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Endocyte, Inc. Common Stock position peaked at $66K in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.